- 1 Distinct and synergistic immunological responses to SARS-CoV-2 and
- 2 Mycobacterium tuberculosis during co-infection identified by single-cell-
- 3 RNA-seq
- 4 Dylan Sheerin^{1,2,*}, Thanh Kha Phan^{1,3}, Emily M. Eriksson^{2,4}, COVID PROFILE Consortium, Anna

```
5 K. Coussens ^{1,2,5,*}
```

- 6 ¹ Infectious Diseases and Immune Defence Division, Walter and Eliza Hall Institute of Medical
- 7 Research, VIC 3052, Australia
- 8 ² Department of Medical Biology, The University of Melbourne, VIC 3052, Australia
- ⁹ ³ La Trobe Institute for Molecular Science, Department of Biochemistry and Chemistry, School of
- 10 Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Australia
- ⁴ Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research,
- 12 VIC 3052, Australia
- 13 ⁵ Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular
- 14 Medicine, Department of Pathology, University of Cape Town, South Africa
- 15 *** Correspondence:**
- 16 Dylan Sheerin; sheerin.d@wehi.edu.au
- 17 Anna Coussens; coussens.a@wehi.edu.au
- 18
- Keywords: Tuberculosis, COVID-19, whole blood, scRNA-seq, apoptosis, cell death, TNF,
 interferon, HIVE.

21 Abstract

22

23 COVID-19 and tuberculosis (TB) exhibit similar symptomatic presentation, clinical parameters and 24 co-diagnosis increases COVID-19 mortality yet there is limited understanding of the mechanisms 25 underlying their immunopathogenic interactions. Here we show by single-cell RNA-sequencing of 26 18,990 cells from whole blood uninfected or infected with Mycobacterium tuberculosis (Mtb), 27 SARS-CoV-2, or both pathogens, their shared, distinct, and synergistic immunological interactions. 28 The greatest transcriptional divergence occurred within monocytes and two neutrophil subsets at 29 early timepoints of infection. Co-infection had the greatest synergistic effect 24 hours post-infection 30 including enrichment of IFN- γ and TNF production, whilst 96 hours post-infection *Mtb*, SARS-CoV-31 2 and co-infection shared considerable pathway overlap. SARS-CoV-2 infection alone resulted in 32 widespread cell death 96 hours post-infection, whilst Mtb and co-infection had enhanced cell survival 33 at 96 hrs, sharing negative regulation of extrinsic apoptosis. Our findings elucidate potential 34 pathways for targeted host-directed therapies, which is particularly crucial for settings where these 35 pathogens are now endemic.

36

37

38

39

40 Introduction

The COVID-19 pandemic has had a substantial impact on global progress towards tuberculosis 41 (TB) elimination, primarily through disruptions to TB diagnosis and treatment services^{1,2}. There 42 43 was a precipitous drop in TB notifications in 2020 and, according to numbers derived from the most 44 recent World Health Organization report, annual deaths from TB have increased between 2019 and 2021 for the first time since 2005^3 , reversing a trend of slow but sustained decline. Beyond 45 46 impacting TB health services, the Global Tuberculosis Network conducted a prospective multi-47 country register-based cohort study involving 175 centres across 37 countries, identifying 767 48 dually diagnosed TB/COVID-19 patients which provided evidence that TB patients suffer worse outcomes when co-infected by COVID-19⁴. They found that TB/COVID-19 patients experienced 49 50 11.1% mortality, compared to 1-2% for COVID-19 alone. A large multi-variate analysis of 51 3,460,932 patients in South Africa found that current and previous TB increased COVID-19 52 mortality with adjusted hazard ratios of 2.7 and 1.5, respectively⁵. Despite these epidemiological 53 findings, the immunopathologic interaction between TB and COVID-19 that increases mortality 54 risk remains poorly understood.

55 The effects of co-infection with Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 on host 56 immune responses have scarcely been explored in the literature to date. Most published studies have 57 focused on the impact of co-infection on antigen-specific responses to *Mtb* and SARS-CoV-2. 58 These studies have reported that active (clinical) TB limits interferon (IFN)-y responses to SARS-CoV-2 antigen *in vitro*⁶, that COVID-19 patients have lower levels of *Mtb*-specific CD4+ T cells⁷ 59 and that "latent" TB infection alters humoral responses to SARS-CoV-2 infection⁸ and vice versa⁹. 60 61 A mouse study of *Mtb*/SARS-CoV-2 co-infection demonstrated alteration of the cytokine profile and loss of granulomatous control of *Mtb* in the lung, leading to *Mtb* dissemination¹⁰. Most recently, 62 63 immune profiling of TB/COVID-19 co-infected patients revealed significant impairment of antigen-64 specific responses to the virus and diminished *in vitro Mtb*-specific responses in co-infected patients

65	compared with those with TB-only ¹¹ . Taken together, these data demonstrate an alteration of the
66	ability of the host to respond to and control Mtb and/or SARS-CoV-2 in the event of co-infection,
67	prompting further exploration of the underlying immunological pathways.

68	We previously performed a patient-level meta-analysis of published COVID-19 immune cell
69	signatures on publicly available TB RNA-seq datasets to identify potential immunological hotspots
70	that could exacerbate disease, identifying neutrophil, monocyte, lung macrophage subpopulations,
71	interferon and complement signalling particularly shared between severe COVID-19 and active and
72	subclinical TB ¹² . However, a detailed exploration of the responses to genuine co-infection in
73	humans was lacking. We therefore elected to study these responses in human whole blood at single-
74	cell (sc) resolution by subjecting blood samples from four healthy adults to ex vivo infection with
75	Mtb and/or SARS-CoV-2 for subsequent scRNA-seq at 24 and 96 hours post-infection (p.i.). By
76	defining longitudinal gene expression changes induced by each infectious agent, relative to
77	uninfected samples, and comparing these responses with co-infected samples, we were able to
78	discern unique aspects of the immune response to each pathogen and which responses are
79	exacerbated by co-infection. The present study provides the most comprehensive overview of the
80	immunological interaction between these two globally significant pathogens to date.
0.1	

81

82 **Results**

83 Pathogen-specific changes in immune cell proportions recovered from peripheral blood

84 emerge over the course of *ex vivo* infection

Peripheral blood collected from four healthy donors, all COVID-19 vaccinated, two with documented PCR-positive mild/moderate COVID-19 and two without were collected on different days and cultured either uninfected or infected with *Mtb*, SARS-CoV-2, or both pathogens simultaneously for 24 and 96 hours. Cells were captured, preserved and stored in HIVE scRNA-seq

89 devices and then batch processed for scRNA-seq library preparation and sequencing. Following 90 acquisition of scRNA-seq data, quality control analysis was first performed on the raw scRNA-seq 91 data acquired from each individual sample from our 8 biological conditions: uninfected, *Mtb*-only, 92 SARS-CoV-2-only (SARS-only) and co-infection, at 2 time points. Each sample was then filtered 93 to exclude cells with <500 genes/transcripts and >15% of reads mapping to mitochondrial genes 94 (indicative of dying cells). This resulted in total cell counts ranging from 367-3,894 (median 95 2,340), and an overall total of 18,990 cells (Table 1). Normalisation and feature selection were 96 performed prior to data integration, and dimensionality reduction was subsequently performed on 97 the integrated data. ANPEP, a gene which encodes alanine aminopeptidase, a receptor known to 98 facilitate the binding and entry of coronaviruses, was the top gene contributing to the first principal 99 component (PC1) of the data (Fig. 1a). In addition to multiple genes involved in macrophage and 100 endothelial cell adhesion and migration, RAB31, which encodes a GTPase implicated in the 101 maturation of phagosomes which engulf *Mtb*, was among the top 10 genes contributing to PC1 (Fig. 102 1a).


103 Fourteen clusters were identified based on underlying gene expression differences in the integrated 104 data which were broadly categorised by applying cell type annotation into eight distinct immune 105 cell populations (Fig. 1b). The integrated data were then split by infection condition at each time 106 point to begin comparing cell clusters (Fig. 1c). Yields for each cell type were similar overall 107 between 24 hours and 96 hours p.i. for the uninfected and *Mtb*-only samples, but there was fewer 108 cells recovered in the SARS-only and co-infected samples at 96 h p.i (Fig. 1c, Table 1). SARS-only 109 had the lowest number of cells recovered at this time point, with just 367 remaining after quality 110 filtering (Table 1). Neutrophils made up a greater proportion of the SARS-only and co-infected 111 samples at 24 hours p.i. (68% and 52% of recovered cells, respectively) compared to uninfected and 112 *Mtb*-only (27% and 23%, respectively), with SARS-only having the lowest proportions of CD4+ T 113 cells, CD8+ T cells, B cells and natural killer (NK) cells of all four conditions (Supplementary Fig.


114	1). This represented a 17	7% and 12% increase for each of t	he two identified neutrophil p	opulations
115	in the SARS-only sample	ples, relative to the uninfected	samples, while the second j	population
116	accounted for a 33% incr	rease in the co-infected samples (F	ig. 1d). At 96 hours p.i., severa	al immune
117	cell populations were me	ore abundant in the Mtb-only san	pples relative to the uninfecte	d samples
118	(Fig. 1d, Table 1), includ	ling B cells (88%), LPS-responding	g neutrophils (95%), NK cells	(35%) and
119	CD4+ T cells (33%). Wi	th the exception of B cells, the late	er 3 cell types were also all hig	gher in the
120	co-infected samples com	pared with the SARS-only sample	es at this timepoint, suggesting	; <i>Mtb</i> may
121	be	sustaining	their	viability.

	24 hours post-infection				96 hours post-infection			
Cell type	Uninfected	<i>Mtb</i> -only	SARS-only	Co-infected	Uninfected	<i>Mtb</i> -only	SARS-only	Co-infected
Monocytes	2158	1106	904	740	2601	1464	190	588
Neutrophils	451	158	979	318	317	92	38	60
(GM-CSF/IFN-y)								
Neutrophils (LPS)	618	297	1313	820	93	181	17	56
CD8+ T cells	304	145	70	87	339	275	47	81
CD4+ T cells	247	176	47	138	259	344	46	143
NK cells	67	63	17	55	55	74	15	42
HSC	34	24	48	28	29	34	9	14
(G-CSF)								
B cells	15	12	2	15	8	15	5	3
Total	3894	1981	3380	2201	3701	2479	367	957
(18,990 cells)								

Table 1. Cell counts for each of the remaining cells belonging to each annotated immune cell population after quality control filtration for each infection condition and timepoint.

3






130 donors, identified by shared nearest neighbour modularity optimisation. Clusters are here grouped 131 according to either the 14 identified clusters (0-13, left) or one of eight distinct immune cell type 132 annotations (right). c UMAP plots depicting clustering of cells separated for the four conditions (x-133 axis) and two timepoints (y-axis) and coloured by the eight distinct immune cell type annotations. 134 Cell number for each condition/timepoint listed in Table 1. d Bar plots depicting the percentage 135 change in cell count for each of the annotated cell clusters relative to the uninfected samples at the 136 same timepoint, for each infection condition. HSC, haematopoietic stem cell; NK, natural killer; 137 SARS, SARS-CoV-2.

138

139 Distinct immunological pathway enrichment highlights cells responding to infection

140 For the 14 identified clusters, covering the eight distinct immune cell populations, GO and Reactome 141 biological process (BP) pathway enrichment analyses were performed to determine whether they 142 were associated with distinct immune functions. Pathways were filtered to display the most salient 143 terms in Fig. 2, with the full lists provided in Supplementary Tables 1-2. Clusters 1, 2, 5 and 7 were 144 associated with the greatest number of significantly enriched pathways. While clusters 2 and 5 are 145 both predicted to be neutrophil populations, cluster 2 is characterised by its response to GM-CSF and 146 IFN- γ , whereas cluster 5 is characterised by its greater enrichment of response to LPS. Cluster 5 was 147 found predominantly in the SARS-only and co-infected samples at 24 hours p.i. (Fig. 1c); clusters 3 148 and 6 were also classified as LPS-responding neutrophils but were not associated with statistically 149 significant enrichment of these pathways at this timepoint. The GM-CSF/IFN-y-responding 150 neutrophils were associated with the largest number of significantly enriched GO pathways and, as 151 predicted by their annotation, they were defined by response to IFN- γ , production of TNF, cytokine 152 signalling, endocytosis and neutrophil migration (Fig. 2a). Furthermore, this cluster was significantly

153 enriched for Reactome pathways denoting IFN- α/β signalling, Fc- γ receptor-dependent phagocytosis 154 and interleukin signalling (Fig. 2b). The genes implicated in the enrichment of the interleukin 155 signalling term included pro-inflammatory mediators and chemokines SOD2, IRAK1, PTAFR, IL1B, 156 SYK, TNFRSF1B, CXCL2, CSF3R, HCK, CCL3L1, GRB2, CCL20, CDKN1A, CXCL1, STAT1, 157 CCR1, MAP3K8, IL1R1, CXCL10, VEGFA, IL1A and PTPN12. Conversely, the LPS-responding 158 neutrophils were exclusively significantly enriched for GO pathways indicating metal ion 159 sequestration and homeostasis (LCN2, FTL, TFR2, LTF, PRNP, SLC39A7, SLC11A1, S100A8 and 160 S100A9), regulation of leukocyte cell-cell adhesion, response to chemokine (also confirmed by 161 Reactome pathway analysis, Fig. 2b), and negative regulation of cell adhesion and IFN- γ production 162 (Fig. 2a). Clusters 1, 7 and 10 represent subsets of monocytes, with clusters 1 and 7 both enriched for 163 antigen processing and presentation via MHC class II. Cluster 7 is exclusively enriched for peptide 164 antigen assembly with MHC class II protein complex, whilst Cluster 1 is exclusively enriched for 165 myeloid leukocyte migration, superoxide anion generation and membrane lipid catabolic process and 166 Cluster 10 is exclusively enriched for foam cell differentiation (ITGAV, PPARG, MSR1, NR1H3, 167 IL18, ITGB3 and LPL).



168

169 Fig. 2 Substantial immune pathway enrichment underpins identified cell clusters and exhibits 170 greatest divergence between conditions at 24 hours post-infection. 14 identified clusters of cells 171 were consolidated to eight immune cell populations based on cluster annotation. Cell marker genes 172 were identified by performing a Wilcoxon Rank Sum tests between each of the eight annotated 173 immune cell populations, irrespective of sample. These differentially expressed gene (DEG) lists 174 were then subjected to a biological process (BP) enrichment analysis using a gene ontology (GO) or 175 **b** Reactome pathway annotation. False discovery rate-adjusted 2-sided *p*-values are represented by 176 the shading of data points, while the size corresponds to the number of significant genes (count) 177 implicated in that pathway. A pseudobulk analysis was performed between infection conditions at 178 each timepoint by combining cells in each condition and using standard differential expression (DE) 179 methods, with each of the four composite donor IDs as replicates. Significant DEGs were then

subjected to a BP GO enrichment analysis and the overlap in GO terms was assessed by venn
diagram at c 24 hours and d 96 hours post-infection. Co-infected, *M. tuberculosis (Mtb)* and SARSCoV-2 (SARS) infected.

183

184 Co-infection demonstrates synergistic global immune pathway enrichment at 24 hours, and 185 greater shared pathways by 96 hours, of infection

186 To ascertain whether differences in immunological pathway enrichment existed between each 187 infection condition, compared to uninfected, a pseudobulk analysis was performed using donor IDs 188 as biological replicates and performing differential expression analyses across all cell types between 189 conditions. A similar GO and Reactome pathway enrichment analysis (Fig. 2A-B, Supplementary 190 Table 3-4) was then performed on the significant genes identified (Supplementary Table 5-10). 191 Assessing the unique and overlapping significantly enriched terms revealed distinct aspects of the 192 immune response invoked by each infection condition, at both time points. At 24 hour p.i SARS-only 193 and coinfection shared the greatest overlap in terms (222), compared to only 39 commonly enriched 194 terms between *Mtb*-only and co-infection however, this pattern was switched at 96 hours p.i. with 195 *Mtb*-only and co-infection sharing 114 terms compared to only 62 shared terms between SARS-only 196 and co-infection. This demonstrates that the influence of each pathogen on the transcriptome 197 changes during the course of co-infection, with the influence of *Mtb* increasing during co-infection as 198 it replicates over time.

Looking at terms unique to each pathogen, 105 were enriched for *Mtb*-only and 89 for SARS-only at 24 hours p.i.. Of the biologically relevant GO terms for this analysis, certain generic immune cell activation pathways and immune effector processes were uniquely enriched in *Mtb*-only infected cells at 24 hours p.i., while B cell activation (GO:0042113), Fc receptor and STAT signalling

203 (GO:0038094, GO:0097696), and several other cell signalling/response to cytokine GO terms were 204 unique to SARS-only infection (Supplementary Table 3). Amongst the 222 enriched terms shared 205 between SARS-only and co-infection at 24 hours p.i. were $\alpha\beta$ T cell activation and differentiation 206 (GO:0046631, GO:0046632), antimicrobial humoral immune response mediated by antimicrobial 207 peptide (GO:0061844), negative regulation of extrinsic apoptotic signalling (GO:2001237), 208 extracellular matrix disassembly (GO:0022617), negative regulation of cell-cell adhesion 209 (GO:0022408), positive regulation of phagocytosis (GO:0050766), regulation of coagulation 210 (GO:0050818), IFN-γ signalling (GO:0034341), IL-1/2/6 production (GO:0032612, GO:0032623, 211 GO:0032635), leukocyte/lymphocyte proliferation (GO:0070661, GO:0046651) and migration 212 (GO:0050900, GO:0072676), antigen processing and presentation (GO:0019882) and defence 213 response to virus (GO:0051607). Amongst, the 39 terms shared between *Mtb*-only and co-infection at 214 24 hours p.i. included seven related to cell cycle/division, and others relating to endothelial cell 215 migration (GO:0043542) and regulation of cell differentiation (GO:0045595, Supplementary Table 216 3).

217 By 96 hour p.i. Mtb-only and co-infection were enriched for 114 shared terms including negative 218 regulation of extrinsic apoptotic signalling (GO:2001240) and TNF production (GO:0010804), 219 antigen processing and presentation via MHC class II (GO:0002495), cell death in response to 220 oxidative stress (GO:0036473), iron homeostasis (GO:0006879), endothelial cell migration and 221 proliferation (GO:0043542, GO:0001935), LPS metabolic process (GO:0008653), and reactive 222 nitrogen species (GO:2001057); while SARS-only and co-infection shared 62 terms including 223 myeloid cell differentiation (GO:0030099), pattern recognition receptor/TLR signalling 224 (GO:0002221, GO:0002224) and positive regulation of reactive oxygen species metabolic process 225 (GO:2000379). At 96 hours p.i *Mtb* infection had only 16 unique terms (of its total 389), including 226 WNT signalling (GO:0016055), whereas SARS-only infection had the largest number of enriched

13

227 terms and the largest number of unique terms at this time (513 of 834 terms, ~62%, Fig. 2d). 228 However, the unique terms included many variations on terms collectively shared between all three 229 infection conditions at this timepoint (described below) with the additional enrichment of $\alpha\beta$ T cell 230 activation and differentiation (GO:0046631, GO:0046632), ephrin receptor signalling pathway 231 (GO:0048013), Fc epsilon receptor signalling (GO:0038095), granulocyte migration (GO:0097530), 232 intrinsic apoptotic signalling (GO:0097193), macrophage activation (GO:0042116), IL-2/6/8 233 production (GO:0032623, GO:0032635, GO:0032637), monocyte chemotaxis (GO:0002548), and 234 response to IL-1 (GO:0071347) and type I IFN (GO:0034340); many of these terms being shared 235 between SARS-only and co-infection at 24 hours p.i. Thus, over the time course of infection very 236 few of these pathways were unique to SARS-CoV-2 with the majority regulated at one time by both 237 pathogens, just the kinetics varying. Finding the largest enrichment of pathways in the SARS-only 238 infected cells at 96 hours p.i. with this also being the condition with smallest cell recovery, suggests 239 the dominance of the immune response to SARS infection in the absence of *Mtb* co-infection, with 240 the increased cell recovery for co-infected samples perhaps due to survival signals induced by *Mtb* 241 infection.

242 Next, when comparing how the pathogens interact during co-infection, first comparing the similarity 243 between all three conditions (i.e. terms shared with no synergistic effect of co-infection) there were 244 only 18 collectively shared terms at 24 hour p.i (Fig. 2c), all of which were related to generic 245 biological functions and not specific to infection (Supplementary Table 3). By contrast, co-infection 246 was associated with 238 uniquely enriched terms the largest number across all infection conditions at 247 24 hours p.i., indicating the synergistic nature of the response to dual infection, identifying terms not 248 induced by either pathogen alone (Fig. 2c); uniquely enriched terms included IFN- γ and TNF 249 production (GO:0034341, GO:0034612), lymphocyte activation/differentiation (GO:0046649, 250 GO:0030098), NK cell-mediated immunity (GO:0002228), T cell signalling (GO:0050852) and

251 positive regulation of viral process (GO:0048525). However by 96 hours p.i. only 6 terms where 252 unique to the co-infection group, indicating limited synergistic pathway enrichment, but there were 253 now 182 terms common between *Mtb*-only, SARS-only and co-infection (Fig. 2d); these included 254 antimicrobial humoral response, B cell activation, T cell differentiation, reactive oxygen species 255 processes, regulation of viral life cycle, lipoprotein metabolic process, tissue remodeling and receptor 256 mediated endocytosis (Supplementary Table 4). Together this shows that *Mtb* and SARS-CoV-2 257 share a large overlap in immune pathway enrichment which they each induce during infection with 258 early synergism during co-infection.

Finally, at 24 hours p.i there were an additional 10 terms commonly enriched in *Mtb*-only and SARSonly, not shared by co-infection, increasing to 77 commonly enriched terms for the two monoinfections at 96 hours p.i. These terms would be independently but not synergistically regulated by each pathogen, and may include pathways were each pathogen has opposing effects such that during co-infection pathway enrichment is lost.

264

Specific differences between infection conditions are most apparent in innate populations and within the first 24 hours of infection


To further examine specific differences and overlapping gene expression between the infection conditions a second pseudobulk analysis was performed, this time at the level of annotated immune cells. For each of the infection conditions, immune cell populations were contrasted against the equivalent cell type in the uninfected group for that timepoint. No significant DEGs were detected in the B cell or haemopoietic stem cell (G-CSF) populations, likely due to the small numbers of cells of this type per donor/condition. The LPS-responding neutrophils at 24 hours p.i. were associated with the greatest number of DEGs across all groups (1,470), with the majority of these induced by co-

274 infection and SARS-only (1,260 total, 434 unique, Supplementary Fig. 2), followed next by 275 monocytes (772 total DEG) and neutrophils (GMCSF) (626 total DEG) at 24 hours p.i. For all cell 276 types with associated differential expression, there were very few DEGs uniquely associated with 277 *Mtb*-only at 24 hours p.i., at which timepoint SARS-only and co-infection induced the greatest DE, 278 while *Mtb*-only and co-infection induced the greatest DE at 96 hours p.i. when SARS-only induced 279 the least DE of all three conditions (Supplementary Fig. 2). This supports a more acute unique 280 transcriptional perturbation associated with SARS-CoV-2 at the initial stages of infection, while *Mtb* 281 induces a response shared by SARS-CoV-2 and co-infection early on which becomes more distinct 282 from SARS-CoV-2 at the later time point after infection is established. The co-infected samples 283 remained highly transcriptionally active throughout both timepoints due to the presence and 284 synergism of both pathogens.

285 Clustering by DEGs identified for monocyte and neutrophil populations generated the cleanest 286 sample clustering by infection condition and timepoint (Fig. 3a compared with NK, CD4+ and CD8+ 287 T cell populations (Supplementary Fig. 3). At 24hr p.i monocyte expression clustered together for 288 *Mtb*-only and co-infection, whilst co-infection had the most unique monocyte expression at 96 hours 289 p.i., with Mtb-only and SARS-only clustering more closely together at this later timepoint. 290 Conversely, patterns of neutrophil gene expression clustering were most distinct at 24 hours p.i at 291 which time GM-CSF neutrophils shared a similar expression pattern between *Mtb*-only and SARS-292 only infections, whilst LPS neutrophils clustered together for co-infection and SARS-only.

Finally, the functional enrichment underlying these similarities and differences was assessed at each timepoint. At 24 hours p.i., the majority of enriched pathways were shared by SARS-only and coinfected samples and related to type I IFN responses from monocytes, neutrophils and CD4+ and CD8+ T cells, cell activation (IL-15, IL-23, TNF) of monocytes and neutrophils (GM-CSF, RIG-I like receptor signalling of monocytes, neutrophils (GM-CSF) and CD4+ T cells and viral sensing &

immunity; IRF2 targets networks for monocytes and both neutrophil subsets (Fig. 3b, Supplementary Table 11). By comparison, there less cell-specific pathway enrichment at 96 hours p.i., with more enrichment at this timepoint shared between *Mtb*-only and co-infection, or all three infection conditions, with monocytes showing the greatest pathway enrichment, particularly for antigen presentation (II & III) and MHC-TLR7-TLR8 cluster, lysosomes in monocytes and both neutrophils and protein synthesis across all cell types, except neutrophils (GM-CSF) (Fig. 3c, Supplementary Table 12).





305 306 Fig. 3 Cell-specific immunological pathway enrichment distinguishes single infection conditions 307 and highlights synergistic activation in co-infected samples. Pseudobulk differential expression 308 (DE) analysis was performed by splitting samples by annotated cell type and comparing these cell 309 types from each infection condition with those of the uninfected samples at each timepoint, using 310 donor IDs as biological replicates. The resultant signatures of significant genes were then used for

hierarchical clustering across all samples, represented by the heatmaps in **a**; the heat of the tiles correspond to the row z-score for a particular gene across all samples. Lists of significant genes for each cell type from each condition were subjected to blood transcriptional module analysis to identify significantly enriched pathways associated with immune cells at **b** 24 hours post-infection and **c** 96 hours post-infection. False discovery rate-adjusted 2-sided *p*-values are represented by the shading of data points, while the size corresponds to the number of significant genes implicated in that module.

317

318 **Discussion**

319 In the present study, we expand upon our previous work which identified overlapping transcriptional networks of circulating immune cells isolated from TB and COVID-19 patients ¹² by delineating host 320 321 immune cell gene expression programs in response to direct whole blood infection with Mtb and 322 SARS-CoV-2 infection. Importantly, we directly compare responses induced by each pathogen alone 323 to what occurs in the context of direct co-infection with both pathogens bringing us closer to an 324 understanding of what is happening at a cellular level during TB/COVID-19 dual presentation. We 325 define the host response pathways underlying differences between immune cell populations reacting 326 to each infection condition across timepoints that appropriately capture innate and adaptive immune 327 cell activity.

Despite the extensive use of bulk RNA-seq to study TB disease mechanisms in the blood of patients, there is but one study that defines host responses to *Mtb* by scRNA-seq in this compartment in which they sequenced PBMCs, excluding granulocytes¹³. There is substantial evidence that neutrophil gene expression is an important marker of TB progression¹⁴⁻¹⁶, so any comprehensive characterisation of TB responses in human blood must include them. Despite their absence from a large number of blood scRNA-seq datasets, the COVID-19 scRNA-seq studies that did sequence neutrophils as part of

334 whole blood found them to be an important cell type for distinguishing patients on the basis of 335 disease severity^{17,18}. In our study, two neutrophil clusters emerged based on gene expression markers, 336 neutrophils characterised by their response to GM-CSF/IFN-y and those with enhanced response to 337 LPS. The later were recovered in greater abundance in SARS-only and co-infected blood at 24 hours 338 p.i, whilst only the GM-CSF neutrophils were enriched uniquely in SARS-only infection. Based on 339 GO enrichment analyses, GM-CSF neutrophils appeared to have greater enrichment of IFN- γ and TNF regulation. These are both key cytokines implicated in *Mtb* control¹⁹⁻²¹, so the fact they are not 340 341 enriched to the same levels during co-infection, although they were more abundant than in *Mtb*-342 infection alone, suggests *Mtb* is interfering with their regulation by SARS-CoV-2. We previously 343 identified IFN- γ and TNF signalling in the top 20 shared transcriptional pathways in blood of 344 COVID-19 and TB patients and demonstrated in vitro that SARS-CoV-2 infected macrophages 345 increase TNF and IFNG expression when pre-incubated in the inflammatory milieu of Mtb infected 346 macrophages, correlating with increased SARS-CoV-2 transcript levels¹². IFN- γ and TNF have been 347 shown to act synergistically in a mouse model of COVID-19 by increasing inflammatory cell death through a process termed 'PANoptosis'²². Cell death was also exclusively significantly enriched in 348 349 these neutrophils in the SARS-only samples at 24 hours p.i.. Given the dramatic cell death observed 350 at 96 hours p.i. in SARS-only and co-infected samples, with greater loss of cell recovery in SARS-351 only compared with co-infected, it is possible that early production of these cytokines from 352 neutrophils may be one of the mechanisms underpinning this. A number of apoptosis regulation GO 353 terms were significantly enriched in SARS-infected samples, with or without Mtb co-infection, at 24 354 hours p.i, including apoptotic cell clearance, extrinsic and intrinsic apoptotic signalling pathways, 355 leukocyte and lymphocyte apoptotic processes and terms associated in the regulation of these 356 pathways (Supplementary Table 3). At 96 hours p.i Mtb-only and co-infection shared enrichment of 357 negative regulation of extrinsic apoptosis, which may underpin the increased recovered of cells from 358 co-infected compared to SARS-only infected blood at 96 hours p.i. Caspase 8, the mediator of

extrinsic apoptosis, has been identified as a critical factor in triggering inflammatory processes the lead to immunopathology in the lungs of COVID-19 patients²³. Furthermore, caspase 8-dependent T cell apoptosis has been associated with T cell lymphopenia in severe COVID-19 patients, but this process could be prevented *ex vivo* with the use of pan-caspase inhibitors²⁴. Given the critical role of T cells in *Mtb* control, early intervention to prevent T cell death from occurring in co-infected patients may be required to prevent TB disease progression.

365 Three neutrophil and monocyte cluster signatures were the greatest determinant of differences 366 between the three infection conditions based on hierarchical clustering analyses. This ties in with 367 evidence that innate immune cell gene expression, rather than lymphoid cells, marks the greatest divergence between COVID-19 severity across patients¹⁷. Monocytes were the cell type associated 368 369 with the largest number of significantly enriched pathways, the majority of which were common to 370 SARS-only and co-infected samples, specifically those related to immune activation, type I IFN 371 responses and antigen presentation. Monocytes expressing high levels of HLA-DR and type I IFNs 372 were identified in mild COVID-19 patients in the scRNA-seq study exploring myeloid cell 373 dysregulation¹⁷. It has been shown that the activation status of monocytes are a correlate of COVID-374 19 prognosis, with inflammatory phenotypes associated with poorer outcomes²⁵. Given that certain 375 circulating monocytes have been identified in TB patients which correlate with disease progression, 376 the induction of these activated, proinflammatory monocytes during co-infection may increase the 377 likelihood of TB disease being advanced in co-infected individuals²⁶. By 96 hours p.i. the greatest 378 number of significantly enriched pathways was associated with and common to monocytes from 379 *Mtb*-only and co-infected samples and these pathways were mostly related to lysosome and antigen 380 presentation.

381 The most striking functional response induced by SARS-only/co-infection was the production of 382 IFNs, particularly those classified as type I (α and β). This observation runs counter to some early

383 human studies in which only low levels of type I IFN were measured in COVID-19 patients, 384 irrespective of disease severity²⁷, and subsequent studies that suggested little in the way of IFN gene 385 expression in peripheral blood from COVID-19 patients but an early transient wave of IFNstimulated genes (ISGs)^{17,28}. Mouse studies have indicated that the type I IFN response to SARS-386 CoV-2 contributes more to immunopathology than viral control²⁹. In TB, early expression of ISGs in 387 TB contacts has been linked to disease progression and worsened prognosis^{16,30-32}. Progression from 388 earlier disease states to clinical TB is typically preceded by a wave of ISG expression¹⁶. However, 389 there is also evidence that type I IFN responses can be protective in TB³³, and therefore it is likely 390 391 that the influence of these IFNs on immune cell composition and pathogenesis has a time-dependent effect over the course of TB disease³⁴. It is plausible that modulation of the type I IFN response in 392 393 TB patients with a viral co-infection may alter the balance in such a way as to promote TB disease 394 progression. Over- or under-activation of type I IFN responses is also known to contribute to host 395 pathogenesis for viral infections³⁵, so it is equally likely that an existing *Mtb* infection could 396 negatively impact control of SARS-CoV-2 and promote more severe disease manifestations. Our 397 previous patient-level meta-analysis of COVID-19 signatures on TB datasets indicated that IFN gene 398 signatures associated with COVID-19 severity were highly significantly enriched in whole blood of 399 TB progressors and their expression was the strongest correlate of SARS-CoV-2 replication in macrophages¹², suggesting that the existence of a strong TB IFN signature when SARS-CoV-2 co-400 401 infection occurs could be a key determinant of poor outcomes for TB patients.

402 SARS-only samples had much lower proportions of CD4+ T cell, CD8+ T cell, B cell and NK cell 403 recovery at 24 hours. Longitudinal profiling of lymphocyte subsets in COVID-19 patients showed 404 that this occurs in patients shortly after symptom onset, when severe patients have lower proportions 405 of these cell types than those with mild infections, and they reach a nadir at 4–6 days post symptom 406 onset³⁶. It has been reported that TB/COVID-19 co-infected patients have lower absolute lymphocyte

counts compared with COVID-19 patients⁶. This did not appear to be the case in our study, although 407 408 co-infected samples had lower proportions of lymphocytes than Mtb-only and uninfected samples at 409 24 hours. We also observed a strong IFN signature in CD4+ and CD8+ T cells at 24 hours p.i. in the 410 SARS-only and co-infected samples. A scRNA-seq study of peripheral blood responses in severe 411 COVID-19 patients noted that the most commonly upregulated genes in these patients were ISGs based on their DE comparison with healthy controls³⁷. At 96 hours p.i protein synthesis was 412 413 commonly significantly enriched across all three infection conditions in CD4+ and CD8+ T cells. 414 Enrichment of this pathway appeared to be mostly driven by expression of cathepsin genes, including 415 CTSB and CTSD. These genes encode proteases, mainly found in lysosomes, which have been implicated in *Mtb* survival³⁸ and mediating SARS-CoV-2 binding³⁹. 416

417 The SARS-only samples had a greater proportion of B cells at 96 hours p.i.; several studies have noted an increase in the frequency of plasmablasts in severe COVID-19 patients^{28,40,41}. However, this 418 419 cell type was not captured at sufficient levels to perform any meaningful comparisons between 420 groups to ascertain its function. NK cell proportions remained consistent in *Mtb*-only samples, as has 421 been observed in TB patients compared even with TB-HIV co-infected patients^{42,43}. Only samples 422 that were Mtb-infected had any significant pathway enrichment in NK cells, with enrichment for 423 protein synthesis, including expression of CTSD as well as PSAP and TPT1, at the 96-hour timepoint. 424 There is evidence that NK cell functionality plays a protective role by combating *Mtb* during HIV 425 infection⁴⁴ that may also apply to other co-infections.

Our study is limited by the fact that we are studying the responses to pathogens in an artificial *ex vivo* infection model, so we do not recapitulate the natural course of infection, including the recruitment of new immune cells to replenish dying ones. Little is known about the mechanisms underlying human immune responses to the initial stages of *Mtb* infection as it is difficult to ascertain when exactly this occurs, while symptoms and diagnostics allow this to be better determined for SARS-CoV-2

431 infection. Our use of a reagent, TPCK trypsin, to cleave the SARS-CoV-2 spike glycoprotein and 432 allow entry into host cells that do not express or have low levels of ACE2 receptor during initial 433 infection also means that this model is not entirely representative of what occurs *in vivo*. This was 434 done to increase the number of infected cells in our model, over the sort experimental timecourse. 435 Human neutrophils have high levels of ACE2 expression and would be naturally infected and 436 macrophages have been shown to be infected with SARS-CoV-2 in human lung autopsy sections and to be a site for viral replication⁴⁵. We have also shown human macrophages to have increased 437 438 susceptibility to SARS-CoV-2 infection in the absence of TPCK trypsin addition when incubated in *Mtb* inflammatory milieu¹². Together this suggests there is the potential for ongoing SARS-CoV-2 439 440 infection of immune cells in our model, following TPCK trypsin removal. As not all cells will be 441 infected, this approach allowed us to induce a reliable bystander response in cells that do not take up 442 the virus that could then be compared between conditions. Despite the fact that SARS-CoV-2 transcripts undergo polyadenylation⁴⁶, we were unable to detect any viral transcripts in our count 443 444 matrices. This may be due to insufficient sequencing depth or the capture efficiency of the scRNA-445 seq method used. Finally, simultaneous infection with *Mtb* and SARS-CoV-2 is unlikely to occur in 446 most cases. With an established Mtb infection prior to SARS-CoV-2 infection more likely to reflect 447 the vast majority of cases, as was observed in the TB/COVID Global Study Group report⁴. 448 Nevertheless, in any co-infected individual there will always be new cells coming into an infection 449 site, so that over time, irrespective of the first infecting pathogen, once both are present then any 450 subsequent sequence of infection can occur.

In summary, we provide the first characterisation of human circulating immune cell gene expression changes resulting from direct *Mtb* and SARS-CoV-2 co-infection. We hope these data will provide a valuable resource for researchers and clinicians to gain insights to better characterise and identify

454 points of potential therapeutic intervention or immunological exacerbation in TB/COVID-19 co-455 infected patients.

456

457 Materials and Methods

458 *Mycobacterium tuberculosis* single cell stock generation

459 *Mtb* single cell suspension stock for infection were made using *Mtb* lineage 2 clinical strain MRC57, as previously described¹². Briefly, 10 mL 7H9 (DifcoTM Middlebrook 7H9 broth, Becton 460 461 Dickinson)/ADC (Becton Dickinson) media containing 0.05% Tween-80 (Sigma-Aldrich) were 462 inoculated with Mtb. After 10 days growth at 37°C, 1 ml culture was subcultured into 100 mL 463 7H9/ADC media without Tween-80 and incubated at 37°C for a further 10 days. Mtb was pelleted by 464 centrifugation, and then single cell suspensions made by shaking with ~ 10 glass beads (2–3 mm, 465 Sigma-Aldrich) with successive washes in PBS and low speed centrifugation. Stocks were made in 466 PBS/5% glycerol and stored at -80°C. One fresh and one frozen aliquot was serially diluted and 467 plated in quadruplicated on three-sector 7H10 (Difco™ Middlebrook 7H10 agar, Becton 468 Dickinson)/ADC plates for colony forming unit (CFU) determination, incubated at 37°C and counted 469 after 10, 14 and 21 days.

470 SARS-CoV-2 stock preparation

SARS-CoV-2 stocks for infections were made using isolate VIC001 (24/03/21, obtained from The
Peter Doherty Institute for Infection and Immunity, Melbourne, Australia), as previously described¹².
Briefly, vero (CCL-81, ATCC) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM
+ 1 g/L D-glucose, L-glutamine and 110 mg/L sodium pyruvate) + 10% heat-inactivated foetal
bovine serum (FBS) until confluent. After washing in PBS, 2.5 mL serum-free DMEM containing

SARS-CoV-2 MOI of 0.01 (1 x 10^5 tissue culture infectious dose 50 (TCID50) for ~1 x 10^7 cells) 476 477 and 1 µg/mL TPCK-treated trypsin was added and cells incubated at 37°C with 5% CO₂ for 30 478 minutes. 20 mL of serum-free DMEM + TPCK trypsin was added to the flask and incubated at 37°C 479 with 5% CO₂ for 48 hours or until sufficient cytopathic effect was observed under the microscope. 480 Infection media was centrifuged to pellet debris and 1 ml aliquots of supernatants stored at -80°C. To 481 determine infection stock TCID50, vero cells were seeded in flat-bottomed 96-well plates at 1×10^4 482 cells/well and incubated at 37°C with 5% CO₂ overnight to achieve confluency. Cells were washed 483 twice with PBS and then cultured in 5-step 1:7 serial dilutions with six replicates/dilution in serum-484 free DMEM + TPCK and incubated for four days at 37°C with 5% CO₂. TCID50 values were 485 calculated by scoring wells (positive or negative) for cytopathic effect (CPE) on day four, using the 486 Spearman and Kärber method⁴⁷.

487 Blood collection

488 Acquisition of human blood samples and immunological investigations were approved by the Human 489 Research Ethics Committee at the Walter and Eliza Hall Institute (WEHI HREC #18_09LR and 490 #20/08) and Melbourne Health (RMH69108) as part of the COVID PROFILE study, a longitudinal cohort of convalescent COVID-19 patients and uninfected contacts⁴⁸. Sample and study data were 491 collected and managed using REDCap^{49,50} electronic data capture tools hosted by Clinical Discovery 492 493 and Translation, WEHI, Parkville, Victoria, Australia. All subjects provided written informed 494 consent to participate in this study, in accordance with the Declaration of Helsinki. Participants were 495 selected to represent broad demographics of the population: equal age, sex and previous COVID-19 496 distribution, all COVID-19 vaccinated. Blood was collected in sodium heparin tubes from four 497 healthy participants (2 males [29/47 yrs] and 2 females [23/45 yrs]), three of whom self-identified as 498 being Oceanian (e.g. Australian, Aboriginal, Maori) and one (older female) as People of the 499 Americas (e.g. Hispanic, Brazilian, Mexican, Jamaican). All four had received 2 doses of either

500 Comirnaty (Pfizer/BioNTech) or ChAdOx1-S (Oxford/AstraZeneca). Blood from each participant 501 were divided into eight 500 μ L aliquots (approximately 2.5 x 10⁶ cells/aliquot) for two timepoints (24 502 and 96 hours) and four conditions – uninfected, *Mtb*-infected, SARS-infected and co-infected in 10 503 ml tubes.

504 **Blood infections**

505 For SARS-CoV-2 infection, blood samples were pelleted at 300 x g for 10 minutes, plasma were transferred to a sterile 2mL tube, cells were resuspended in 1 mL of 2.4 x 10⁶ (TCID50/mL) viral 506 507 particles of SARS-CoV-2 (MOI 1) in RPMI + TPCK trypsin and incubated at 37°C with 5% CO₂ for 508 30 minutes. After incubation, cells were pelleted, infection media removed, and autologous plasma 509 was replaced. For SARS-CoV-2 only infected samples, 500 µL RPMI was then added. Mtb-only and co-infected blood samples were infected with 500 μ L RPMI containing *Mtb* at 5.5 x 10⁴ CFU/ml. An 510 511 equivalent volume of RPMI as also added to uninfected samples. All samples were placed on an 512 orbital rotator in a 37°C incubator with 5% CO₂ for 24 or 96 hours.

513 Single-cell RNA-sequencing

514 Cells were harvested at the appropriate timepoint by pelleting at 300 x g for 5 minutes, removing 515 supernatant, resuspending pellets in an appropriate volume of red blood cell lysis solution (0.15 M 516 NH₄Cl, 0.01 M KHCO₃, 0.1mM EDTA), incubating for 10 minutes and repeating with an RPMI 517 wash. Cells in a 1 mL RPMI suspension were counted using a Countess automated cell counter 518 (ThermoFisher). Equal numbers of cells from each of the four donors were combined in pairs (one 519 male and one female sample) for each condition and a total of 16 HIVETM (Honeycomb 520 Biotechnologies) cell capture devices, two for each condition, were loaded with 30,000 total cells 521 according to manufacturer's instructions for cell preservation and storage at -80°C until ready for

further processing. The HIVETM devices were processed to cDNA, after pooling conditions and timepoints at equimolar concentrations to yield one indexed library for each condition and timepoint (eight in total), according to manufacturer's instructions (v1 revision A). Final library concentrations were measured using a KAPA Library Quantification Kit (KAPA Biosystems) and profiled on a Tapestation (Agilent) before pooling at equimolar concentrations for Illumina NextSeq 2000 (Illumina) sequencing with custom primers (Honeycomb Biotechnologies), with the base calling and quality scoring performed by the Real Time Analysis (v2.4.6) software.

529 Data analysis

530 The bespoke HIVETM BeeNetTM pipeline (v1.1, Honeycomb Biotechnologies,
531 <u>https://honeycombbio.zendesk.com/hc/en-us/articles/4408694864283-BeeNet-v1-1-X-Software-</u>

532 Guide) was used to process the raw data into count matrices. First of all, the *make-ref* function was 533 used to generate a human reference genome index from the GRCh38 Homo sapiens reference 534 genome fasta and annotation gtf files (https://ftp.ensembl.org/pub/release-109/fasta/homo_sapiens/). 535 Fastq files were aligned to this index using the BeeNetTM align function and transcript count matrices 536 were obtained for each sample. To demultiplex the four donors combined in each sample, cellsnplite⁵¹ was used to pileup expressed alleles in the data and vireo⁵² was subsequently used to assign 537 538 cells to donors. Donor ID probabilities obtained from these algorithms were used as metadata for 539 downstream analyses requiring biological replicates.

540 The Seurat pipeline applied matrices for downstream analyses was to count 541 (https://satijalab.org/seurat/). A Seurat object was created for each of the eight samples, combined 542 into a merged Seurat list and subjected to quality control filtration. Features with fewer than 50 genes 543 and 50 unique transcripts were removed and a threshold of <15% mitochondrial reads was used to 544 filter down to the final total cell numbers per sample for analysis. The low gene and transcript

545 thresholds were set to keep cell types with low numbers of expressed genes, particularly neutrophils, 546 in the analysis. Each object in the merged list was subjected to log normalization and variable feature identification, using variance stabilising transformation and 2000 features⁵³. Objects were integrated 547 548 by selecting integration features, finding integration anchors based on these features and using the integration anchors as input for the Seurat IntegrateData function⁵⁴. The resultant integrated data 549 550 object was scaled and subjected to principal component (PC) analysis before graph-based K-nearest 551 neighbour cluster identification was performed. Non-linear dimensionality reduction was performed 552 using uniform manifold approximation and projection (UMAP) on the first 10 dimensions.

Cell type annotation was conducted using SingleR and the Human Primary Cell Atlas Data obtained via the celldex package⁵⁵. Cluster markers were identified by running the Seurat *FindAllMarkers* function using the default Wilcoxon Rank-Sum test to define differentially expressed genes (DEG). Gene ontology (GO) and Reactome pathway enrichment analysis were performed using the identified markers and by invoking the org.Hs.eg.db, AnnotationDbi and clusterProfiler packages⁵⁶. A stringent 2-sided *p*-value cut-off of 0.001 was applied after Benjamini Hochberg adjustment for multiple testing.

560 To perform pseudobulk differential expression analysis, the Seurat object was first converted to a 561 SingleCellExperiment class. Cluster counts and metadata for each donor were then aggregated and extracted and used to create DESeq2⁵⁷ objects. Counts were transformed for clustering analyses 562 563 (Supplementary Fig. 4) before running the DESeq function. Log₂ fold-change (LFC) shrinkage and 564 Wald tests were performed for each contrast of interest to obtain results tables for all genes. Those 565 with false-discovery rate (FDR)-adjusted 2-sided p-values <0.05 and LFC values >0.58 were deemed 566 significant (Supplementary Table 5-10). GO analyses of pseudobulk data were performed using the clusterProfiler⁵⁶ and tmod⁵⁸ packages. 567

568 Data availability

- 569 The raw fastq files and processed transcript count matrices for this study can be found in the gene
- 570 expression omnibus database under the accession number GSEXXXXXX. The scripts used to
- analyse these data have been uploaded to GitHub XXXXXX.

572 **References**

573 1 McQuaid, C. F., Vassall, A., Cohen, T., Fiekert, K. & White, R. G. The impact of COVID-19 574 on TB: a review of the data. Int J Tuberc Lung Dis 25, 436-446 (2021). 575 2 Migliori, G. B. et al. Gauging the impact of the COVID-19 pandemic on tuberculosis 576 services: a global study. European Respiratory Journal 58, 2101786 (2021). 577 3 World Health Organization. Global tuberculosis report 2022. (2022). 578 4 The TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: 579 description of the global cohort. European Respiratory Journal 59, 2102538 (2022). 580 5 Western Cape Department of Health in collaboration with the National Institute for 581 Communicable Diseases South Africa. Risk Factors for Coronavirus Disease 2019 (COVID-582 19) Death in a Population Cohort Study from the Western Cape Province, South Africa. *Clin* Infect Dis 73. e2005-e2015 (2021). 583 584 6 Petrone, L. et al. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro 585 respond to SARS-CoV-2. Int J Infect Dis 113 Suppl 1, S82-s87 (2021). 586 7 Riou, C. et al. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity 587 and impact of HIV-1 and tuberculosis coinfection. The Journal of Clinical Investigation 131 (2021). 588 589 8 Rajamanickam, A. et al. Latent tuberculosis co-infection is associated with heightened levels 590 of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection. 591 Journal of Infection 83, 339-346 (2021). 592 9 Rajamanickam, A. et al. Effect of SARS-CoV-2 seropositivity on antigen – specific cytokine 593 and chemokine responses in latent tuberculosis. Cytokine 150, 155785 (2022). 594 10 Hildebrand, R. E. et al. Superinfection with SARS-CoV-2 Has Deleterious Effects on 595 Mycobacterium bovis BCG Immunity and Promotes Dissemination of Mycobacterium 596 tuberculosis. Microbiology Spectrum 10, e03075-03022 (2022). 597 11 Najafi-Fard, S. et al. Characterization of the immune impairment of tuberculosis and COVID-598 19 coinfected patients. International Journal of Infectious Diseases (2023). 599 12 Sheerin, D. et al. Immunopathogenic overlap between COVID-19 and tuberculosis identified 600 from transcriptomic meta-analysis and human macrophage infection. *iScience* 25, 104464 601 (2022).602 13 Cai, Y. et al. Single-cell transcriptomics of blood reveals a natural killer cell subset depletion 603 in tuberculosis. EBioMedicine 53 (2020). 604 14 Berry, M. P. R. et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977 (2010). 605 606 15 Bloom, C. I. et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, 607 pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 8, e70630 (2013). 608 Scriba, T. J. et al. Sequential inflammatory processes define human progression from M. 16 609 tuberculosis infection to tuberculosis disease. *PLoS Pathog* **13**, e1006687 (2017). 610 17 Schulte-Schrepping, J. et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell 611 Compartment. Cell 182, 1419-1440.e1423 (2020).

- 612 18 Silvin, A. *et al.* Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate
 613 Severe from Mild COVID-19. *Cell* 182, 1401-1418.e1418 (2020).
- 614 19 Cooper, A. M. *et al.* Disseminated tuberculosis in interferon gamma gene-disrupted mice. J
 615 *Exp Med* 178, 2243-2247 (1993).
- 616 20 Flynn, J. L. *et al.* An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. *J Exp Med* **178**, 2249-2254 (1993).
- Flynn, J. L. *et al.* Tumor necrosis factor-alpha is required in the protective immune response
 against Mycobacterium tuberculosis in mice. *Immunity* 2, 561-572 (1995).
- Karki, R. *et al.* Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell
 Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock
 Syndromes. *Cell* 184, 149-168.e117 (2021).
- Li, S. *et al.* SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8
 activation. *Signal Transduction and Targeted Therapy* 5, 235 (2020).
- André, S. *et al.* T cell apoptosis characterizes severe Covid-19 disease. *Cell Death & Differentiation* 29, 1486-1499 (2022).
- 25 Zhang, D. *et al.* Frontline Science: COVID-19 infection induces readily detectable
 morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. *J Leukoc Biol* 109, 13-22 (2021).
- Lastrucci, C. *et al.* Tuberculosis is associated with expansion of a motile, permissive and
 immunomodulatory CD16+ monocyte population via the IL-10/STAT3 axis. *Cell Res.* 25,
 1333-1351 (2015).
- 633 27 Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe
 634 COVID-19 patients. *Science* 369, 718 (2020).
- Arunachalam, P. S. *et al.* Systems biological assessment of immunity to mild versus severe
 COVID-19 infection in humans. *Science* 369, 1210-1220 (2020).
- 637 29 Israelow, B. *et al.* Mouse model of SARS-CoV-2 reveals inflammatory role of type I
 638 interferon signaling. *J Exp Med* 217 (2020).
- 30 Zak, D. E. *et al.* A blood RNA signature for tuberculosis disease risk: a prospective cohort
 study. *Lancet* 387, 2312-2322 (2016).
- 641 31 Singhania, A. *et al.* A modular transcriptional signature identifies phenotypic heterogeneity of
 642 human tuberculosis infection. *Nat Commun* 9, 2308 (2018).
- 643 32 Esmail, H. *et al.* Complement pathway gene activation and rising circulating immune
 644 complexes characterize early disease in HIV-associated tuberculosis. *Proceedings of the*645 *National Academy of Sciences* 115, E964-E973 (2018).
- 64633Zhang, G. *et al.* A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased647resistance to tuberculosis in humans. *Nature Communications* 9, 85 (2018).
- 64834Desvignes, L., Wolf, A. J. & Ernst, J. D. Dynamic roles of type I and type II IFNs in early649infection with Mycobacterium tuberculosis. J Immunol 188, 6205-6215 (2012).
- 650 35 Mesev, E. V., LeDesma, R. A. & Ploss, A. Decoding type I and III interferon signalling
 651 during viral infection. *Nat Microbiol* 4, 914-924 (2019).

- Liu, J. *et al.* Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. *eBioMedicine* **55** (2020).
- Wilk, A. J. *et al.* A single-cell atlas of the peripheral immune response in patients with severe
 COVID-19. *Nat. Med.* 26, 1070-1076 (2020).
- Bires, D. *et al.* Role of Cathepsins in Mycobacterium tuberculosis Survival in Human
 Macrophages. *Sci Rep* 6, 32247 (2016).
- 39 Zhang, Q. *et al.* Molecular mechanism of interaction between SARS-CoV-2 and host cells
 and interventional therapy. *Signal Transduction and Targeted Therapy* 6, 233 (2021).
- Mathew, D. *et al.* Deep immune profiling of COVID-19 patients reveals distinct
 immunotypes with therapeutic implications. *Science* 369 (2020).
- Kuri-Cervantes, L. *et al.* Comprehensive mapping of immune perturbations associated with
 severe COVID-19. *Sci Immunol* 5 (2020).
- 42 Ardain, A. *et al.* Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. *Nature* 570, 528-532 (2019).
- Roy Chowdhury, R. *et al.* A multi-cohort study of the immune factors associated with M.
 tuberculosis infection outcomes. *Nature* 560, 644-648 (2018).
- Allen, M. *et al.* Mechanisms of Control of Mycobacterium tuberculosis by NK Cells: Role of
 Glutathione. *Front Immunol* 6, 508 (2015).
- 670 45 Sefik, E. *et al.* Inflammasome activation in infected macrophages drives COVID-19
 671 pathology. *Nature* 606, 585-593 (2022).
- 672 46 Chang, J. J. *et al.* Long-Read RNA Sequencing Identifies Polyadenylation Elongation and
 673 Differential Transcript Usage of Host Transcripts During SARS-CoV-2 In Vitro Infection.
 674 *Front Immunol* 13, 832223 (2022).
- 675 47 Ramakrishnan, M. A. Determination of 50% endpoint titer using a simple formula. *World J*676 *Virol* 5, 85-86 (2016).
- 67748Emily, M. E. *et al.* Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID678PROFILE). *medRxiv*, 2023.2004.2027.23289157 (2023).
- Harris, P. A. *et al.* Research electronic data capture (REDCap)--a metadata-driven
 methodology and workflow process for providing translational research informatics support. J *Biomed Inform* 42, 377-381 (2009).
- 68250Harris, P. A. *et al.* The REDCap consortium: Building an international community of683software platform partners. *J Biomed Inform* **95**, 103208 (2019).
- Huang, X. & Huang, Y. Cellsnp-lite: an efficient tool for genotyping single cells. *Bioinformatics* 37, 4569-4571 (2021).
- Huang, Y., McCarthy, D. J. & Stegle, O. Vireo: Bayesian demultiplexing of pooled singlecell RNA-seq data without genotype reference. *Genome Biology* 20, 273 (2019).
- 688 53 Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq
 689 data using regularized negative binomial regression. *Genome Biol* 20, 296 (2019).
- 690 54 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* 177, 1888-1902.e1821
 (2019).

- Aran, D. *et al.* Reference-based analysis of lung single-cell sequencing reveals a transitional
 profibrotic macrophage. *Nature Immunology* 20, 163-172 (2019).
- Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. *The Innovation* 2 (2021).
- Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. *Genome Biology* 15, 550 (2014).
- 58 Zyla, J. *et al.* Gene set enrichment for reproducible science: comparison of CERNO and eight
 other algorithms. *Bioinformatics* 35, 5146-5154 (2019).
- 700

701 Acknowledgments

- The authors thank Honeycomb Biotechnologies Inc. for allowing us to participate in their early
- access program, Coussens Lab members for feedback, the WEHI PC3 Facility manager Kathryn
- 704 Davidson for facility support, the WEHI Genomics R&D team, especially Rory Bowden, Daniela
- 705 Zalcenstein, Daniel Brown and Ling Ling, for their input regarding experimental design and analysis,
- the Pellegrini Lab at WEHI for providing Vero cells and input into SARS-CoV-2 assays, and Stephen
- 707 Wilcox of the WEHI Genomics Facility for performing Illumina sequencing of samples. D.S. is
- supported by WEHI and NHMRC (2020750). A.K.C. is funded by WEHI, philanthropic donors,
- NHMRC (2020750) and the Australian Respiratory Council. This work was made possible through
- 710 Victorian State Government Operational Infrastructure Support and Australian Government NHMRC
- 711 IRIISS. The COVID Profile study was supported by WHO Unity funds and WEHI Philanthropic
- funds. The funders had no role in study design, data collection and analysis.

713 Author Contributions

D.S. and A.K.C. conceived and designed the study. E.E. directed the COVID PROFILE clinical study, arranged blood sample collection, SARS-CoV-2 serotyping, and critically reviewed the manuscript. A.K.C. and E.E funded the study. T.K.P. generated SARS-CoV-2 virus stocks and critically reviewed the manuscript. D.S. generated *Mtb* stocks. D.S. performed blood infection

- 718 experiments and processed samples for scRNA-seq. D.S. performed the data analysis. D.S. prepared
- the manuscript with editorial input and revisions from A.K.C. All authors approved the manuscript
- submission.

721 **Competing interests**

The authors declare no competing interests.